arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Shattuck Labs, Inc.

STTK
$7.26 ▲ +0.11 (+1.54%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
30 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
26
Health
Poor
Bearish
auto_awesome

Analytical Summary

Shattuck Labs, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $814.8M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -12.8%
FCF / Share $-0.12
Trailing P/E
Price / Book 5.7x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

30-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-14.77M
↓ -7.8%
Operating Margin Operating profit as % of sales
30.7%
↑ +106.3%
FCF / Share Free cash flow per share
$-0.12
↑ +49.3%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
14
Cash Quality
55

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 30 quarters